Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

176.95 +5.22 (+3.04%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
71 72 Next >
Can AbbVie Stock Keep Outpacing the S&P 500?
AbbVie has been a surprisingly strong performer of late. Can the stock keep it up? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
AbbVie's Parkinson's Disease Therapy Hits FDA Roadblock
AbbVie received an FDA Complete Response Letter for ABBV-951 (foscarbidopa/foslevodopa) due to third-party manufacturing issues. ABBV-951, a treatment for advanced Parkinson's, is approved in 34... 
Via Benzinga
Exposures Product Safety
3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Above-average yields and reliable cash flows make these dividend-paying stocks an income-seeking investor's dream come true. 
Via The Motley Fool
Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income
Buying dividend stocks for income is a smart investment strategy to juice your portfolio's returns even in down markets. 
Via InvestorPlace
Check Out What Whales Are Doing With ABBV
Via Benzinga
AbbVie Stock Price Forecast: $200 On The Cards?
Strategic partnerships and acquisitions enhance AbbVie's pipeline. 
Via Talk Markets
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend. 
Via Talk Markets
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
Via Talk Markets
3 Biotech Stocks to Buy Now: June 2024
These are the three best biotech stocks to buy for long-term returns and portfolio stability due to their target patient populations, 
Via InvestorPlace
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for June 2024
Discover top retirement stocks with strong buy ratings, offering reliable growth and income to ensure a comfortable retirement. 
Via InvestorPlace
Topics Retirement
Exposures Pension
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year
The power of compounding can build huge amounts of passive income. 
Via The Motley Fool
Earn Income While Playing The Hottest Sectors
Via Talk Markets
Looking Into AbbVie's Recent Short Interest
Via Benzinga
Comparative Study: AbbVie And Industry Competitors In Biotechnology Industry
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,100 Today
Via Benzinga
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
Discover these blue-chip stocks to buy in the biotechnology, banking, pharmaceuticals, tobacco, restaurants, and entertainment industries. 
Via InvestorPlace
3 High-Dividend Stocks to Buy and Hold Forever: June 2024 Edition
Looking for high-yield dividend stocks to buy and hold? Take a look at these three buy-rated Dividend Aristocrats. 
Via InvestorPlace
2 Super Smart Dividend Stocks to Buy With $10,000 Right Now
Don't sleep on the value of quality dividends. 
Via The Motley Fool
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having... 
Via Benzinga
2 Dividend Stocks That Could Pay You for Life
There are other reasons to love these businesses, too. 
Via The Motley Fool
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
The Dividend Defenders: 3 Stocks That Will Protect and Grow Your Wealth Dividend Stocks
Are you looking for some defenders for your portfolio? Here are three dividend stocks to protect and grow your wealth. 
Via InvestorPlace
Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts
Thanks to the predictability of big businesses, the bargains found among undervalued blue-chip stocks are simply more trustworthy. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.